The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Open accessPublished version of a preprint
Abstract
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2 1-5. Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC 50 values) as low as 2 ng ml-1. In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of these NAb responses appear to correlate with viral load, with higher responses reported in patients with more severe disease, and in older adults compared with younger adults26–29.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In agreement with previous reports3,6,9, there was a broad range of plasma neutralizing activity 3–14 weeks after the second vaccine dose that was similar to that elicited by natural infection in a convalescent cohort after 1.3 months, and greater than the activity at 6.2 months after infection (Fig. 1a, Extended Data Table 1).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SARS-CoV-2 infection rapidly elicits nAbs (16, 21–24) that decline, but remain detectable, over several months (25–29).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spike is the target of SARS-CoV-2 neutralizing antibodies, and the receptor binding domain (RBD) of Spike is the target of >90% of neutralizing antibodies in COVID-19 cases (Brouwer et al., 2020; Piccoli et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Suthar et al., 2020), with some neutralizing antibodies instead targeting the N-terminal domain (NTD) (Liu et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although it is unclear how long protective effects last beyond the first few months after vaccination, some studies suggest that the elicited neutralizing activity is maintained for up to 8 months after the natural infection with SARS-CoV-2 (refs. 41,42).”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [41]
Experimental — accuracy not yet measured
In the citing paper
“8 weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers3,5,6.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“In line with previous reports3,6,9, IgG and IgM levels were significantly higher in the vaccinated group compared to a cohort of convalescent patients assayed 1.3 and 6.2 months after infection, while IgA levels were similar (Extended Data Fig 1j–l).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“We limited our analysis to RBD because plasma RBD antibodies are strongly correlated with neutralizing activity3,10–12.”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Consistent with this observation, there was an overall increase in the apparent avidity of plasma antibodies between 1.3 and 12 months3,4 (P < 0.0001) (Extended Data Fig. 7c).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Most serum nAb responses elicited during natural infection are directed at the RBD (21, 23, 30, 31).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Numerous neutralizing anti-RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, 22–24, 32–37).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Analyses of the B cell responses to the spike generally focus on the RBD and on cells sorted with RBD baits introducing an inherent bias by omitting non-RBD targets”
From SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“The neutralizing antibodies are produced by B cells with a wide range of heavy chain and light chain V genes (Robbiani et al., 2020; Rogers et al., 2020). SARS-CoV-2 neutralizing antibodies also exhibit little to no somatic hypermutation (Gaebler et al., 2020; Robbiani et al., 2020; Rogers et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“Although neutralizing antibody titers have not correlated with reduced COVID-19 severity (Dan et al., 2021; Piccoli et al., 2020; Robbiani et al., 2020), SARS-CoV-2 cTfh cell frequencies have been associated with reduced disease severity (Rydyznski Moderbacher et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“This appears to hold true in the case of SARS-CoV-2, where neutralizing antibody titers (and total Spike antibody titers) have positively correlated with COVID-19 disease severity in large cohort studies (Piccoli et al., 2020; Robbiani et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“However, it should also be noted that circulating SARS-CoV-2 neutralizing antibody titers are relatively low in a substantial fraction of recovered COVID-19 cases (Dan et al., 2021; Robbiani et al., 2020; Wajnberg et al., 2020), indicating that either the neutralizing antibody potency or the serum concentration is suboptimal in this subset.”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,927
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,136
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T. M., Willey, R. L., Rabson, A. B., & Martín, M. Á. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,805
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Cited by
Sorted by citations
Items 201–300 of 1,017
Stabilizing the closed SARS-CoV-2 spike trimer
Juraszek, J., Rutten, L., Blokland, S., Bouchier, P., Voorzaat, R., Ritschel, T., Bakkers, M. J. G., Renault, L. L. R., & Langedijk, J. P. M. (2021) · Nature Communications · doi:10.1038/s41467-020-20321-x · Cited by 157
Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York
Annavajhala, M. K., Mohri, H., Wang, P., Nair, M., Zucker, J. E., Sheng, Z., Gomez-Simmonds, A., Kelley, A. L., Tagliavia, M., Huang, Y., et al. (2021) · doi:10.1101/2021.02.23.21252259
Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals
Zhang, F., Gan, R., Zhen, Z., Hu, X., Li, X., Zhou, F., Liu, Y., Chen, C., Xie, S., Zhang, B., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00263-y · Cited by 156
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 155
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
Watanabe, Y., Mendonça, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F. R., Davies, H. D., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00080 · Cited by 155
Cao, Y., Jian, F., Zhang, Z., Yisimayi, A., Hao, X., Bao, L., Yuan, F., Yu, Y., Du, S., Wang, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111845 · Cited by 154
Zhou, P.-P., Song, G., Liu, H., Yuan, M., He, W., Beutler, N., Zhu, X., Tse, L. V., Martinez, D. R., Schäfer, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.005 · Cited by 154
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.015 · Cited by 153
Schmitz, A., Weber, A., Bayin, M., Breuers, S., Fieberg, V., Famulok, M., & Mayer, G. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202100316 · Cited by 152
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651
“Plasma 50 samples were from blood drawn approximately 1 month post-symptom onset (Table S1), shown to be 51 close to the antibody response peak [16, 17].”
BackgroundSelf-citationCurrent Prevention of COVID-19: Natural Products and Herbal Medicine
Huang, J., Tao, G., Liu, J., Cai, J., Huang, Z., & Chen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588508 · Cited by 151
Tas, J. M. J., Koo, J., Lin, Y., Xie, Z., Steichen, J. M., Jackson, A. M., Hauser, B. M., Wang, X., Cottrell, C. A., Torres, J. L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.020 · Cited by 151
Chai, K. L., Valk, S. J., Piechotta, V., Kimber, C., Monsef, I., Doree, C. J., Wood, E. M., Lamikanra, A., Roberts, D. J., McQuilten, Z., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub3 · Cited by 150
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150
Self-citationAntibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
Ge, J., Wang, R., Ju, B., Zhang, Q., Sun, J., Chen, P., Zhang, S., Tian, Y., Shan, S., Cheng, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20501-9 · Cited by 149
Brochot, É., Demey, B., Touzé, A., Belouzard, S., Dubuisson, J., Schmit, J. L., Duverlie, G., François, C., Castelain, S., & Helle, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.584251 · Cited by 148
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147
Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection
Elledge, S. K., Zhou, X. X., Byrnes, J. R., Martinko, A. J., Lui, I., Pance, K., Lim, S. A., Glasgow, J. E., Glasgow, A. A., Turcios, K., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00878-8 · Cited by 146
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
Pang, N. Y., Pang, A. S., Chow, V. T. K., & Wang, D. Y. (2021) · Military Medical Research · doi:10.1186/s40779-021-00342-3 · Cited by 146
Wang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 145
Self-citationHow to interpret and use COVID-19 serology and immunology tests
Ong, D. S. Y., Fragkou, P. C., Schweitzer, V. A., Chemaly, R. F., Moschopoulos, C. D., & Skevaki, C. L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.001 · Cited by 144
Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management
Aslan, A., Aslan, C., Zolbanin, N. M., & Jafari, R. (2021) · Pneumonia · doi:10.1186/s41479-021-00092-9 · Cited by 144
Antibody and B cell responses to SARS-CoV-2 infection and vaccination
Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 143
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
Vibholm, L. K., Nielsen, S. S. F., Pahus, M. H., Frattari, G. S., Olesen, R., Andersen, R., Monrad, I., Andersen, A. H. F., Thomsen, M. M., Konrad, C. V., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103230 · Cited by 142
Antibody Responses in COVID-19: A Review
Chvatal‐Medina, M., Cortina, Y. A. M., Grajales, P. J. P., Velilla, P. A., & Rugeles, M. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633184 · Cited by 142
Deep geometric representations for modeling effects of mutations on protein-protein binding affinity
Liu, X., Luo, Y., Li, P., Song, S., & Peng, J. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009284 · Cited by 140
Moriyama, S., Adachi, Y., Sato, T., Tonouchi, K., Sun, L., Fukushi, S., Yamada, S., Kinoshita, H., Nojima, K., Kanno, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.015 · Cited by 140
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N. M., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 139
Zhou, Y., Liu, Z., Li, S. N., Xu, W., Zhang, Q., da Silva, I. T., Li, C., Wu, Y., Jiang, Q., Liu, Z., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108699 · Cited by 137
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Pymm, P., Adair, A., Chan, L., Cooney, J. P., Mordant, F. L., Allison, C. C., López, E., Haycroft, E. R., O’Neill, M. T., Tan, L. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101918118 · Cited by 137
Galson, J. D., Schätzle, S., Bashford-Rogers, R. J. M., Raybould, M. I. J., Kovaltsuk, A., Kilpatrick, G. J., Minter, R., Finch, D. K., Dias, J. C., James, L. K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605170 · Cited by 136
A humanized mouse model of chronic COVID-19
Sefik, E., Israelow, B., Mirza, H., Zhao, J., Qu, R., Kaffe, E., Song, E., Halene, S., Meffre, E., Kluger, Y., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01155-4 · Cited by 136
Self-citationSARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
Tea, F., Stella, A. O., Aggarwal, A., Darley, D. R., Pilli, D., Vitale, D., Merheb, V., Lee, F. X. Z., Cunningham, P., Walker, G. J., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003656 · Cited by 135
Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.011 · Cited by 135
Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection
Kaku, C. I., Bergeron, A. J., Ahlm, C., Normark, J., Sakharkar, M., Forsell, M. N. E., & Walker, L. M. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq3511 · Cited by 135
Dugan, H. L., Stamper, C. T., Li, L., Changrob, S., Asby, N. W., Halfmann, P. J., Zheng, N.-Y., Huang, M., Shaw, D. G., Cobb, M. S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.001 · Cited by 134
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Gasparo, R. D., Pedotti, M., Simonelli, L., Nickl, P., Muecksch, F., Cassaniti, I., Percivalle, E., Lorenzi, J. C. C., Mazzola, F., Magrì, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03461-y · Cited by 134
Self-citationDetection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
West, A. P., Wertheim, J. O., Wang, J. C., Vasylyeva, T. I., Havens, J. L., Chowdhury, M. A., Gonzalez, E., Fang, C. E., Lonardo, S. S. D., Hughes, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25168-4 · Cited by 134
Self-citationLusvarghi, S., Pollett, S. D., Neerukonda, S. N., Wang, W., Wang, R., Vassell, R. A., Epsi, N. J., Fries, A. C., Agan, B. K., Lindholm, D. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8543 · Cited by 133
Disease diagnostics using machine learning of B cell and T cell receptor sequences
Zaslavsky, M., Craig, E., Michuda, J., Sehgal, N., Ram-Mohan, N., Lee, J.-Y., Nguyen, K. D., Hoh, R. A., Pham, T. D., Röltgen, K., et al. (2025) · Science · doi:10.1126/science.adp2407 · Cited by 132
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes
Li, Y., Schneider, A. M., Mehta, A., Sade-Feldman, M., Kays, K. R., Gentili, M., Charland, N. C., Gonye, A. L. K., Gushterova, I., Khanna, H. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148635 · Cited by 130
Persistent cellular immunity to SARS-CoV-2 infection
Breton, G., Mendoza, P., Hägglöf, T., Oliveira, T. Y., Schaefer-Babajew, D., Gaebler, C., Turroja, M., Hurley, A., Caskey, M., & Nussenzweig, M. C. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202515 · Cited by 129
Self-citationLi, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S. Y., Tauzin, A., Gasser, R., Vézina, D., Anand, S. P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110210 · Cited by 128
Dogan, M., Kozhaya, L., Placek, L., Gunter, C., Yiğit, M., Hardy, R., Plassmeyer, M. L., Coatney, P., Lillard, K., Bukhari, Z., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01649-6 · Cited by 126
Convalescent Plasma Therapy for COVID-19: State of the Art
Focosi, D., Anderson, A. O., Tang, J. W.-T., & Tuccori, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-20 · Cited by 125
Flower, B., Brown, J. C., Simmons, B., Moshe, M., Frise, R., Penn, R., Kugathasan, R., Petersen, C., Daunt, A., Ashby, D., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2020-215732 · Cited by 124
Yu, F., Xiang, R., Deng, X., Wang, L., Yu, Z., Tian, S., Liang, R., Li, Y., Ying, T., & Jiang, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00318-0 · Cited by 124
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
Mittal, A., Khattri, A., & Verma, V. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010260 · Cited by 124
Klingler, J., Weiß, S., Itri, V., Liu, X., Oguntuyo, K. Y., Stevens, C. S., Ikegame, S., Hung, C.-T., Enyindah-Asonye, G. M., Amanat, F., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa784 · Cited by 123
Cho, H., Gonzales-Wartz, K. K., Huang, D., Yuan, M., Peterson, M., Liang, J. Y., Beutler, N., Torres, J. L., Cong, Y., Postnikova, E. N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5413 · Cited by 123
Beaudoin-Bussières, G., Chen, Y., Ullah, I., Prévost, J., Tolbert, W. D., Symmes, K., Ding, S., Benlarbi, M., Gong, S. Y., Tauzin, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110368 · Cited by 122
Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2020) · eScholarship (California Digital Library) · Cited by 121
He, L., Lin, X., Wang, Y., Abraham, C., Sou, C., Ngo, T., Zhang, Y., Wilson, I. A., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abf1591 · Cited by 121
Neutralizing Antibody Therapeutics for COVID-19
Hurt, A. C., & Wheatley, A. K. (2021) · Viruses · doi:10.3390/v13040628 · Cited by 121
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 121
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
Sholukh, A. M., Fiore-Gartland, A. J., Ford, E. S., Miner, M. D., Hou, Y. J., Tse, L. V., Kaiser, H., Zhu, H., Lu, J., Madarampalli, B., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00527-21 · Cited by 119
Wang, Y., Yuan, M., Lv, H., Peng, J., Wilson, I. A., & Wu, N. C. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.019 · Cited by 119
Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
Gasser, R., Cloutier, M., Prévost, J., Fink, C., Ducas, É., Ding, S., Dussault, N., Landry, P., Tremblay, T., Laforce‐Lavoie, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108790 · Cited by 118
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
Perkmann, T., Perkmann‐Nagele, N., Breyer, M., Breyer‐Kohansal, R., Burghuber, O. C., Hartl, S., Aletaha, D., Sieghart, D., Quehenberger, P., Marculescu, R., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa198 · Cited by 115
Bošnjak, B., Stein, S. C., Willenzon, S., Cordes, A. K., Puppe, W., Bernhardt, G., Ravens, I., Ritter, C., Schultze-Florey, C. R., Gödecke, N., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00573-9 · Cited by 115
Immunoglobulin germline gene variation and its impact on human disease
Mikocziova, I., Greiff, V., & Sollid, L. M. (2021) · Genes and Immunity · doi:10.1038/s41435-021-00145-5 · Cited by 115
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
Tong, P., Gautam, A. K., Windsor, I. W., Travers, M. E., Chen, Y., Garcia, N., Whiteman, N. B., McKay, L. G. A., Storm, N., Malsick, L. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.025 · Cited by 115
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Bates, T. A., Leier, H. C., Lyski, Z. L., McBride, S. K., Coulter, F. J., Weinstein, J. B., Goodman, J. R., Lu, Z., Siegel, S. A. R., Sullivan, P. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25479-6 · Cited by 115
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 115
Neutralizing antibodies targeting SARS-CoV-2 spike protein
Shi, X., Yu, L., Yan, L., Guang, Y., & Qiang, M. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102125 · Cited by 114
Zhang, Q., Ju, B., Ge, J., Chan, J. F., Cheng, L., Wang, R., Huang, W., Fang, M., Chen, P., Zhou, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24514-w · Cited by 114
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays
Tang, M. S., Case, J. B., Franks, C. E., Chen, R. E., Anderson, N. W., Henderson, J. P., Diamond, M., Gronowski, A. M., & Farnsworth, C. W. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa211 · Cited by 113
Jordan, S. C. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13582 · Cited by 113
Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 111
T cell immunity to SARS-CoV-2 following natural infection and vaccination
DiPiazza, A. T., Graham, B. S., & Ruckwardt, T. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.060 · Cited by 109
Tao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 109
Keeton, R., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 109
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Stuart, A. B., Edara, V. V., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109353 · Cited by 108
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26137-7 · Cited by 107
Petersen, L. R., Sami, S., Vuong, N., Pathela, P., Weiss, D., Morgenthau, B. M., Henseler, R. A., Daskalakis, D., Atas, J. G., Patel, A. K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1685 · Cited by 106
Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19
Tosif, S., Neeland, M. R., SUTTON, P. R. N., Licciardi, P. V., Sarkar, S., Selva, K. J., Do, L. A. H., Donato, C. M., Toh, Z. Q., Higgins, R. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19545-8 · Cited by 106
SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors
Benner, S. E., Patel, E. U., Laeyendecker, O. B., Pekosz, A. S., Littlefield, K. E., Eby, Y. J., Fernández, R. E., Miller, J., Kirby, C. S., Keruly, M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa581 · Cited by 105
A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
Li, T., Cai, H., Yao, H., Zhou, B., Zhang, N., van Vlissingen, M. F., Kuiken, T., Han, W., GeurtsvanKessel, C. H., Gong, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24905-z · Cited by 105
Trinité, B., Tarrés-Freixas, F., Rodon, J., Pradenas, E., Urrea, V., Marfil, S., de la Concepción, M. L. R., Ávila‐Nieto, C., Aguilar‐Gurrieri, C., Barajas, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81862-9 · Cited by 104
Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation
King, C., & Sprent, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.003 · Cited by 104
Yates, J. L., Ehrbar, D. J., Hunt, D., Girardin, R. C., Dupuis, A. P., Payne, A. F., Sowizral, M., Varney, S. D., Kulas, K. E., Demarest, V. L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100329 · Cited by 104
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., West, A. P., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.024 · Cited by 104
Self-citationThe immunology of SARS-CoV-2 infections and vaccines
Grigoryan, L., & Pulendran, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101422 · Cited by 102
Chen, E. C., Gilchuk, P., Zost, S. J., Suryadevara, N., Winkler, E. S., Cabel, C. R., Binshtein, E., Chen, R. E., Sutton, R. E., Rodriguez, J. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109604 · Cited by 102
Continuous germinal center invasion contributes to the diversity of the immune response
Hägglöf, T., Cipolla, M., Loewe, M., Chen, S. T., Kara, E. E., Mesin, L., Hartweger, H., ElTanbouly, M. A., Cho, A., Gazumyan, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.032 · Cited by 102
Self-citationRobust SARS-CoV-2 Infection in Nasal Turbinate Despite Systemic Neutralizing Antibody
Zhou, D., Chan, J. F., Zhou, B., Zhou, R., Li, S., Shan, S., Liu, L., Zhang, J., Chen, S. J., Chan, C. C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.019 · Cited by 101
Self-citationSignatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 101
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 101
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
Bracken, C. J., Lim, S. A., Solomon, P. E., Rettko, N. J., Nguyen, D., Zha, B. S., Schaefer, K., Byrnes, J. R., Zhou, J., Lui, I., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00679-1 · Cited by 100
Schäfer, A., Martinez, D. R., Won, J. J., Meganck, R. M., Moreira, F. R., Brown, A. J., Gully, K. L., Zweigart, M. R., Conrad, W. S., May, S. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3410 · Cited by 100
Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
Muri, J., Cecchinato, V., Cavalli, A., Shanbhag, A. A., Matkovic, M., Biggiogero, M., Maida, P. A., Moritz, J., Toscano, C., Ghovehoud, E., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01445-w · Cited by 100
Self-citationLi, Y., Wang, X., & Nair, H. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa436 · Cited by 99
Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment
Ripari, N., Sartori, A. A., Honorio, M. D. S., Conte, F. L., Tasca, K. I., Santiago, K. B., & Sforcin, J. M. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaa067 · Cited by 99
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey‐Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 99
Self-citationBertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abassi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109433 · Cited by 98
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
An, X., Martinez-Paniagua, M. A., Rezvan, A., Sefat, S. R., Fathi, M., Singh, S., Biswas, S., Pourpak, M., Yee, C., Liu, X., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103037 · Cited by 98
Song, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2020) · doi:10.1101/2020.09.22.308965 · Cited by 285
Wu, X., Cheng, L., Fu, M., Huang, B., Zhu, L., Xu, S., Shi, H., Zhang, D., Yuan, H., Nawaz, W., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109869 · Cited by 97
The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients
Luo, H., Jia, T., Chen, J., Zeng, S., Qiu, Z., Wu, S., Li, X., Lei, Y., Wang, X., Wu, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632814 · Cited by 97
Metadata
- Authors
- Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hägglöf, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., Bianchini, F., Chen, S. T., Ramos, V., Patel, R., Dizon, J., Shimeliovich, I., Mendoza, P., Hartweger, H., Nogueira, L., Pack, M., Horowitz, J., Schmidt, F., Weisblum, Y., Michailidis, E., Ashbrook, A. W., Waltari, E., Pak, J. E., Huey-Tubman, K. E., Koranda, N., Hoffman, P. R., West, A. P., Rice, C. M., Hatziioannou, T., Bjorkman, P. J., Bieniasz, P. D., Caskey, M., & Nussenzweig, M. C.
- Affiliations
- Institute for Research in Biomedicine (CH)
- Rockefeller University (US)
- California Institute of Technology (US)
- Chan Zuckerberg Biohub San Francisco (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Robbiani, Davide F.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- ORCID
- Robbiani, Davide F.
- Gaebler, Christian
- Muecksch, Frauke
- Lorenzi, Julio C. C.
- Wang, Zijun
- Cho, Alice
- Agudelo, Marianna
- Barnes, Christopher O.
- Gazumyan, Anna
- Finkin, Shlomo
- Hägglöf, Thomas
- Oliveira, Thiago Y.
- Viant, Charlotte
- Hurley, Arlene
- Hoffmann, Hans-Heinrich
- Millard, Katrina G.
- Kost, Rhonda G.
- Cipolla, Melissa
- Bianchini, Filippo
- Chen, Spencer T.
- Dizon, Juan
- Shimeliovich, Irina
- Mendoza, Pilar
- Hartweger, Harald
- Nogueira, Lilian
- Schmidt, Fabian
- Weisblum, Yiska
- Michailidis, Eleftherios
- Ashbrook, Alison W.
- Waltari, Eric
- Pak, John E.
- Koranda, Nicholas
- Hoffman, Pauline R.
- West, Anthony P.
- Rice, Charles M.
- Bjorkman, Pamela J.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- Venue
- Nature
- Published
- 2020-06-18
- Volume
- 584
- Issue
- 7821
- Pages
- 437-442
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7442695
- OpenAlex
- W3036386821
- Cited by
- 1,853
- References
- 47
- Citations by year
- 2026: 49 · 2025: 79 · 2024: 115 · 2023: 194 · 2022: 403 · 2021: 691 · 2020: 321
- FWCI
- 52.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute (UL1TR001866)
- George Mason University
- California Institute of Technology
- Fast Grants
- National Institutes of Health (P01-AI138398-S1, AI150464, TR001866, UL1TR001866)
- Beckman Institute, California Institute of Technology
- National Institute of Allergy and Infectious Diseases (R01AI091707, R01AI078788, P50AI150464, U19AI111825, P01AI138938, R37AI064003, T32AI070084)
- National Center for Advancing Translational Sciences (TR001866)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, convalescent plasma, neutralizing antibodies, receptor binding domain, spike protein, antibody response, memory B cells, pseudovirus neutralization, vaccine design, antibody epitopes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
